Effect of molecular modification on the inhibition of lymphocyte blastogenesis by cardiac glycosides.
D000818:Animals; D002301:Cardiac Glycosides / Q000494:pharmacology* / Q000633:toxicity; D002415:Cats; D002470:Cell Survival; D002478:Cells, Cultured; D004247:DNA / Q000378:metabolism; D004074:Digitoxin / Q000633:toxicity; D004077:Digoxin / Q000633:toxicity; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects*; D008968:Molecular Conformation; D010042:Ouabain / Q000494:pharmacology; D013936:Thymidine / Q000378:metabolism; D013997:Time Factors
D002301:Cardiac Glycosides; D010042:Ouabain; D004077:Digoxin; D004247:DNA; D004074:Digitoxin; D013936:Thymidine